Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

imeks pharma sdn. bhd. - bisoprolol fumarate -

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

imeks pharma sdn. bhd. - bisoprolol fumarate -

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - infusion (parenteral) - 200 mg - each 10 ml solution contains etoposide

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - infusion (parenteral) - 400 mg - each 20 ml solution contains etoposide

Misri - Kiingereza - EDA (Egyptian Drug Authority)

hexal ag germany - coated tablet - 60 mg

Misri - Kiingereza - EDA (Egyptian Drug Authority)

hexal ag germany - tablet - 100 mg

Misri - Kiingereza - EDA (Egyptian Drug Authority)

hexal ag germany - tablet - 25 mg

Malta - Kiingereza - Medicines Authority

hexal pharma gmbh stella-klein-low-weg 17, 1020 wein, austria - cilostazol - tablet - cilostazol 100 mg - antithrombotic agents

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 70.2 mg (equivalent: sildenafil, qty 50 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; copovidone; saccharin sodium - tigerfil is indicated for the treatment of erectile dysfunction in adult males. tigerfil is not indicated for use by women.